Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07469046) titled 'VAH vs VA in Newly Diagnosed Elderly AML' on Feb. 24.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Condition:
Acute Myeloid Leukemia (AML)
Elderly Patients (60-75 Years)
Intervention:
Drug: Venetoclax
Drug: Azacitidine
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: March 1, 2026
Target Sample Size: 308
Countries of Recruitment:
China
To know more, visit https://clin...